Report: SciGen To Seek Reverse Merger

November 10, 2014 | According to a “Globes” report, the vaccination company SciGen, controlled by Opko Health, will seek out a merger into a shock exchange shell. The company reportedly hopes to maintain its $100 million valuation despite the move, which was initiated Opko Health founder and chairman Phillip Frost. SciGen, which is based in Rehovot, Israel, develops a vaccination for hepatitis B for developing countries, but now the company is looking to bring its products to Europe and the US. The vaccination was originally produced by Israeli company BTG that transferred into Singapore-based SciGen after BTG was liquidated.